dydrogesterone has been researched along with Cardiovascular Diseases in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (81.82) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Kraker, AT; Kenemans, P; Kroeks, MV; Smolders, RG; van der Mooren, MJ | 2 |
| Conard, J; Hellgren, M; Kluft, C; Norris, L | 1 |
| Jick, SS; Meier, CR; Schneider, C | 1 |
| Bühling, KJ; Mueck, AO; Seeger, H | 1 |
| Assumpção, CR; Costa, OS; Kuba, VM; Meirelles, RM; Teixeira, MA | 1 |
| Borowiecka, M; Nowak, P; Połać, I; Wilamowska, A | 1 |
| Kenemans, P; Post, MS; Stehouwer, CD; Teerlink, T; van der Mooren, MJ; Verhoeven, MO | 1 |
| Chang, TC; Chen, M; Chen, RJ; Cheng, SP; Chow, SN; Lien, YR | 1 |
| Lazebniuk, LB; Melchenko, SB | 1 |
| Anderson, RA; Bryden, NA; Bureau, I; Favier, M; Polansky, MM; Roussel, AM | 1 |
1 review(s) available for dydrogesterone and Cardiovascular Diseases
| Article | Year |
|---|---|
Use of dydrogesterone in hormone replacement therapy.
Topics: Breast Neoplasms; Cardiovascular Diseases; Drug Therapy, Combination; Dydrogesterone; Endometrial Hyperplasia; Estradiol; Estrogen Replacement Therapy; Female; Humans; Menopause; Progestins | 2009 |
6 trial(s) available for dydrogesterone and Cardiovascular Diseases
| Article | Year |
|---|---|
Short-term effects of two continuous combined oestrogen-progestogen therapies on several cardiovascular risk markers in healthy postmenopausal women: a randomised controlled trial.
Topics: Adult; alpha-2-Antiplasmin; Antigens; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Drug Combinations; Dydrogesterone; Endothelin-1; Estradiol; Estrogen Replacement Therapy; Factor VII; Female; Fibrinogen; Fibrinolysin; Homocysteine; Humans; Insulin-Like Growth Factor I; Medroxyprogesterone Acetate; Middle Aged; Plasminogen Activator Inhibitor 1; Postmenopause; Risk Factors; Time Factors; Tissue Plasminogen Activator | 2009 |
Cardiovascular risk markers during treatment with estradiol and trimegestone or dydrogesterone.
Topics: Adult; Aged; Biomarkers; Blood Coagulation Factors; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Dydrogesterone; Estradiol; Estrogen Replacement Therapy; Estrogens; Female; Fibrinolysis; Humans; Lipids; Middle Aged; Postmenopause; Progestins; Promegestone; Risk Factors; Thromboembolism; Uterine Hemorrhage | 2009 |
Coagulation and fibrynolitic parameters in women and the effects of hormone therapy; comparison of transdermal and oral administration.
Topics: Administration, Oral; Blood Coagulation; Cardiovascular Diseases; Drug Combinations; Dydrogesterone; Estradiol; Estrogen Replacement Therapy; Estrogens; Female; Fibrinolysis; Humans; Menopause; Middle Aged; Norethindrone; Poland; Postmenopause; Progestins; Risk Factors; Transdermal Patch; Venous Thrombosis | 2013 |
Effect of hormone replacement therapy on plasma levels of the cardiovascular risk factor asymmetric dimethylarginine: a randomized, placebo-controlled 12-week study in healthy early postmenopausal women.
Topics: Arginine; Biomarkers; Cardiovascular Diseases; Chromatography, High Pressure Liquid; Dydrogesterone; Estradiol; Estrogen Replacement Therapy; Female; Humans; Isomerism; Middle Aged; Progesterone Congeners; Promegestone; Risk Factors; Spectrometry, Fluorescence | 2003 |
Effect of conjugated equine estrogen in combination with two different progestogens on the risk factors of coronary heart disease in postmenopausal Chinese women in Taiwan: a randomized one-year study.
Topics: Antithrombin III; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dydrogesterone; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Lipoproteins; Medroxyprogesterone Acetate; Middle Aged; Postmenopause; Prospective Studies; Prothrombin Time; Risk Factors; Triglycerides | 2004 |
The effects of 17 beta-oestradiol plus dydrogesterone compared with conjugated equine oestrogens plus medroxyprogesterone acetate on lipids, apolipoproteins and lipoprotein(a).
Topics: Adult; Aged; Apolipoproteins; Cardiovascular Diseases; Double-Blind Method; Dydrogesterone; Estradiol; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Lipids; Lipoprotein(a); Medroxyprogesterone; Middle Aged; Netherlands; Postmenopause; Prospective Studies; Treatment Outcome; United Kingdom | 2004 |
4 other study(ies) available for dydrogesterone and Cardiovascular Diseases
| Article | Year |
|---|---|
Risk of cardiovascular outcomes in users of estradiol/dydrogesterone or other HRT preparations.
Topics: Cardiovascular Diseases; Case-Control Studies; Databases, Factual; Dydrogesterone; Estradiol; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Myocardial Infarction; Odds Ratio; Risk Factors; Stroke; Time Factors; United Kingdom; Venous Thromboembolism | 2009 |
Dydrogesterone does not reverse the cardiovascular benefits of percutaneous estradiol.
Topics: Administration, Cutaneous; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dydrogesterone; Estradiol; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Progestins; Retrospective Studies; Risk Factors; Triglycerides | 2013 |
[Clinical features of cardiovascular diseases in females with postmenopausal osteoporosis. Femostone treatment in late menopause].
Topics: Cardiovascular Diseases; Drug Combinations; Dydrogesterone; Estradiol; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risk Factors | 2000 |
Beneficial effects of hormonal replacement therapy on chromium status and glucose and lipid metabolism in postmenopausal women.
Topics: Administration, Oral; Blood Glucose; Cardiovascular Diseases; Cholesterol, LDL; Chromium; Dehydroepiandrosterone Sulfate; Diabetes Mellitus, Type 2; Drug Administration Schedule; Dydrogesterone; Estradiol; Estrogen Replacement Therapy; Female; Fructosamine; Humans; Hydrocortisone; Insulin; Leptin; Middle Aged; Postmenopause; Reference Values | 2002 |